Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study
International Journal of Urology · 2026
DOI: 10.1111/iju.70433 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Akihiko Sugino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gunma University Graduate School of Medicine & Gunma University Hospital, Department of Urology, Maebashi, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Active surveillance (AS) offers a strategy to limit unnecessary treatment of prostate cancer while maintaining oncologic safety, yet its adoption in Japan remains limited. To provide Japan‐specific evidence, we evaluated the clinical outcomes of patients undergoing AS at our institution.
Methods
We retrospectively reviewed 86 patients who selected AS between 2012 and 2024. Eligibility criteria included ≤ cT2a disease, prostate‐specific antigen (PSA) level of ≤ 10 ng/mL, Gleason score (GS) of 3 + 3, and 2 or fewer positive cores, with selected inclusion of GS 3 + 4 or 4 + 3 based on patient preference. AS discontinuation was based on clinical or pathological progression or patient preference. This study was approved by the institutional review board of Gunma University (approval no. IRB2025‐033, 2310).
Results
The mean observation period was 48 months. No prostate cancer–specific deaths occurred. AS persistence rates were 89% at 1 year, 55% at 5 years, and 27% at 10 years. Older age (≥ 75 years) was associated with longer AS persistence ( p = 0.021). Overall, 69% of patients underwent repeat biopsy, most commonly at 1 year. Pathological upgrading occurred in 35% at the first and second repeat biopsies and in 20% at the third. Acceptance of the 1‐year repeat biopsy increased from 46% in the early period (2012–2016) to 64% in the later period (2017–2024).
Conclusions
AS demonstrated favorable long‐term safety and durability. Improving adherence to repeat biopsy protocols may further enhance AS management in Japan. Registry and Registration No. of the Study/Trial N/A
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gunma University Graduate School of Medicine & Gunma University Hospital, Department of Urology, Maebashi, Japan.
ORCID-Profile: Akihiko Sugino, Yoshiyuki Miyazawa, Seiji Arai, Yoshitaka Sekine, Kazuhiro Suzuki
Zitieren
APA
Sugino, A., Miyazawa, Y., Nakazawa, S., Tsuji, Y., Fujizuka, Y., Arai, S., Sekine, Y., Nomura, M., Koike, H., Matsui, H., & Suzuki, K. (2026). Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study. International Journal of Urology. https://doi.org/10.1111/iju.70433
Vancouver
Sugino A, Miyazawa Y, Nakazawa S, Tsuji Y, Fujizuka Y, Arai S, et al. Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study. International Journal of Urology. 2026. doi:10.1111/iju.70433
BibTeX
@article{Sugino2026,
author = {Sugino, Akihiko and Miyazawa, Yoshiyuki and Nakazawa, Shun and Tsuji, Yusuke and Fujizuka, Yuji and Arai, Seiji and Sekine, Yoshitaka and Nomura, Masashi and Koike, Hidekazu and Matsui, Hiroshi and Suzuki, Kazuhiro},
title = {Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70433}
}
EUVIMED